Cui Yu-Jie, Liu Jia, Liu Miao-Miao, Zhang Hong-Zhen
Yu-jie Cui, Department of Oncology, Hebei General Hospital, Shijiazhuang, 050051, Hebei, China.
Jia Liu, Department of Hematology, Affiliated Hospital of Hebei University, Baoding, 071000, Hebei, China.
Pak J Med Sci. 2021 Jul-Aug;37(4):1036-1041. doi: 10.12669/pjms.37.4.4066.
To evaluate the clinical effect of apatinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Eighty patients with advanced NSCLC treated in Hebei General Hospital from January 2017 to July 2020 were randomly divided into two groups: the experimental group and the control group, each with 40 cases. Patients in the control group were treated with conventional paclitaxel combined with cisplatin chemotherapy, while patients in the experimental group were treated with apatinib mesylate tablets based on the treatment of the control group. After treatment, tumor efficacy evaluation was conducted on all patients every two cycles, and the therapeutic effect, adverse drug reactions, improvement of quality-of-life scores prior to and after treatment, and changes of indicators such as tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 153(CA153) were compared and analyzed between the two groups.
The total effective rate of the experimental group was 67.5%, which was significantly better than the 45% of the control group (p=0.04); The incidence of adverse drug reactions in the experimental group was 25%, while that in the control group was 37.5%, with no significant difference (p=0.23); Moreover, the improvement rate of quality of life scores in the experimental group was significantly higher than that in the control group (p=0.03), and the levels of CEA and CA153 in the experimental group were significantly lower after treatment than those in the control group, with a statistically significant difference (p=0.01).
Apatinib combined with conventional chemotherapy is effective in the treatment of advanced non-small cell lung cancer, the quality of life can be significantly improved, tumor markers can be significantly reduced, and adverse reactions will not be significantly increased.
评估阿帕替尼联合化疗治疗晚期非小细胞肺癌（NSCLC）的临床疗效。
选取2017年1月至2020年7月在河北医科大学第一医院接受治疗的80例晚期NSCLC患者，随机分为两组：试验组和对照组，每组40例。对照组患者接受常规紫杉醇联合顺铂化疗，试验组患者在对照组治疗基础上加用甲磺酸阿帕替尼片。治疗后，每两个周期对所有患者进行肿瘤疗效评估，比较分析两组患者的治疗效果、药物不良反应、治疗前后生活质量评分改善情况以及癌胚抗原（CEA）、糖类抗原153（CA153）等肿瘤标志物指标的变化。
试验组总有效率为67.5%，显著优于对照组的45%（p=0.04）；试验组药物不良反应发生率为25%，对照组为37.5%，差异无统计学意义（p=0.23）；此外，试验组生活质量评分改善率显著高于对照组（p=0.03），试验组治疗后CEA和CA153水平显著低于对照组，差异有统计学意义（p=0.01）。
阿帕替尼联合传统化疗治疗晚期非小细胞肺癌疗效显著，可显著提高生活质量，显著降低肿瘤标志物，且不会显著增加不良反应。
